Early Antiviral Responses to Rhinovirus Infection in Asthma

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The bulk of the morbidity and mortality related to asthma is during periods of acutely increased symptomatology called 'exacerbations'. Roughly half of asthma sufferers experience such an exacerbation each year. Most of these events are triggered by viral infections, usually the common cold virus (rhinovirus). A key part of the body's defence against viral infections is to produce antiviral proteins called 'interferons', which have a myriad of effects to stop viruses. Previous work on cells taken from volunteers with asthma and healthy controls and infected with rhinovirus in the lab suggests interferon production is impaired in asthma. However when human volunteers with asthma are infected with rhinovirus, high levels of interferon are found a few days later - along with high numbers of virus. Whether the high virus numbers are the result of an initially weak interferon response, with subsequently unchecked viral replication leading to exaggerated interferon levels, is unknown as no one has measured interferons early in infection. By infecting volunteers with asthma and healthy controls with rhinovirus at a known time, only done in a handful of centres worldwide, we will be able to measure interferons within hours of infection and well before symptoms develop.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 55
Healthy Volunteers: t
View:

• Age 18-55 years

• Doctor diagnosis of asthma

• Previous asthma exacerbation

⁃ • Age 18-55 years

Locations
Other Locations
United Kingdom
Imperial College Respiratory Research Unit, St Mary's Hospital
RECRUITING
London
Contact Information
Primary
Research Fellow
imperial.magic@nhs.net
020 7594 3751
Time Frame
Start Date: 2022-08-11
Estimated Completion Date: 2025-08-31
Participants
Target number of participants: 40
Treatments
Asthma
Healthy controls
Related Therapeutic Areas
Sponsors
Leads: Imperial College London

This content was sourced from clinicaltrials.gov